Exchange: NASDAQ·Updated 07:30 PM EST

MBX News

News
all
press releases
HC Wainwright Forecasts MBX Biosciences FY2026 Earnings
MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) - Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for MBX Biosciences in a report issued on Thursday, November 12th. HC Wainwright analyst M. Kapoor expects that the company will earn ($3.13) per share for the ye...
MarketBeat
HC Wainwright Forecasts MBX Biosciences FY2026 Earnings
MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) - Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for MBX Biosciences in a report issued on Thursday, November 12th. HC Wainwright analyst M. Kapoor expects that the company will earn ($3.13) per share for the ye...
MarketBeat
More News
New HHS Direction Creates Potential Opportunities For Peptide Manufacturers, Biotech Companies, And Healthcare Innovators    New York, NY –November 5, 2026 – The federal government’s October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action against qualifying state-licensed pharmacies, federal […] The post Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market appeared first on Financial News Media.
Financial News Media
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels, according to UBS...
CNBC: Top News
MBX Biosciences (NASDAQ:MBX) Trading Down 6.3% - Time to Sell...
MarketBeat
MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat Ratings...
MarketBeat
MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat
Wall Street Zen lowered MBX Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
MBX Biosciences (NASDAQ:MBX) Sees Unusually-High Trading Volume - Time to Buy...
MarketBeat
MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) - Analysts at Lifesci Capital issued their Q1 2026 earnings estimates for MBX Biosciences in a report released on Tuesday, March 31st. Lifesci Capital analyst P. Dolezal anticipates that the company will post earnings of ($0.66) per share for the quar...
MarketBeat
Lifesci Capital raised MBX Biosciences to a "strong-buy" rating in a report on Tuesday...
MarketBeat

Advertisement|Remove ads.